The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension

Intravitreal Injection of Bevacizumab (Avastin) to Treat Posterior Capsule Neovascularization

We report a 64-year-old diabetic woman who developed neovascularization of the posterior capsule 2 years after cataract surgery and intraocular lens implantation. The patient was treated with single injection of 1.25 mg of intravitreal bevacizumab (Avastin) via pars plana. After one week, complete regression of the posterior capsule neovascularization was achieved allowing us to perform Nd: YAG...

Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits

PURPOSE To describe the pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits. METHODS The right eye of 20 rabbits was injected intravitreally with 1.25 mg/0.05 mL bevacizumab. Both eyes of four rabbits each time were enucleated at days 1, 3, 8, 15, and 29. Bevacizumab concentrations were measured in serum, aqueous humor, and vitreous. RESULTS Maximum vitreous (406.25 μg/mL) an...

Testing intravitreal toxicity of bevacizumab (Avastin).

PURPOSE To evaluate the retinal toxicity of varying doses of bevacizumab when injected intravitreally in rabbits. Bevacizumab has been approved by the US Food and Drug Administration for the treatment of metastatic colorectal cancer. MATERIALS AND METHODS Twelve New Zealand albino rabbits were used for this study and divided into four groups. Four concentrations of bevacizumab were prepared: ...

Using intravitreal bevacizumab (Avastin®) – Indian Scenario

Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma.

Neovascular glaucoma is a secondary glaucoma with grave prognosis which follows ischemic retinal disorders in the majority of cases. Mediators that induce new vessel formation such as the vascular endothelial growth factor-A seem to play a key role in the pathophysiology of this condition. Herein, we report 2 cases with neovascular glaucoma secondary to ischemic central retinal vein occlusion w...